Amplia Therapeutics Ltd

$0.120

Day Range

$0.115 – $0.120

52 Week Range

$0.100 – $0.425

Volume

0.00

Avg Volume (10D)

1.27M

Market Cap

$61.60M

Price Chart

Market Statistics

Open$0.120

Previous Close$0.120

Day High$0.120

Day Low$0.115

52 Week High$0.425

52 Week Low$0.100

Valuation

Market Cap61.60M

Shares Outstanding513.31M

Price to Book1.43

Trading Activity

Volume0.00

Value Traded0.00

Bid$0.110 × 69,494

Ask$0.125 × 60,000

Performance

1 Day4.76%

5 Day0.00%

13 Week-2.22%

52 Week44.74%

YTD-26.67%

Technical Indicators

RSI (14)46.14

50-Day SMA$0.140

200-Day SMA$0.143

Amplia Therapeutics Launches New Narmafotinib Ovarian Cancer Study with ANZGOG

Amplia Therapeutics launches PRROSE trial with narmafotinib and ANZGOG in ovarian cancer; 15–20 patients, safety focus, biomarker data.

By Isla Campbell··1 min read min read

Biotechnology

Amplia Therapeutics Halts AMPLICITY Trial Recruitment After Chemo-Related DLTs

Amplia Therapeutics halts AMPLICITY recruitment after DLTs with narmafotinib mFOLFIRINOX; pivots to new combos, delaying readouts and raising investor risk.

By Isla Campbell··1 min read min read

Biotechnology

Amplia Therapeutics Reports Stronger Efficacy and Survival in Pancreatic Cancer Trial

Amplia Therapeutics reports ACCENT trial: 7.8% CR, 35.9% ORR, 11.1-month median OS in pancreatic cancer; trading halt ahead of AACR.

By Isla Campbell··2 min read min read

Biotechnology

Amplia Therapeutics Releases New Topline Data from ACCENT Narmafotinib Pancreatic Cancer Trial

Amplia Therapeutics (ASX: ATX) has released new topline data from an ongoing trial of its best-in-class selective FAK inhibitor narmafotinib on advanced pancreatic cancer. The ACCENT clinical trial is investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of narmafotinib when used in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Latest data to 20 July has […]

By Imelda Cotton··2 min read min read